Edesa Biotech Inc (EDSA) Stock Price, Quote & News

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 289 800 9600

Website: www.edesabiotech.com

Address:

100 Spy Court, Markham, Canada

KennyP007 Sep. 16 at 7:58 PM

$EDSA Fellow TWATS, , next weeks the 4 year anniversary of the BIG POP. Anyone expect any action ???

0 · Reply

BillionerOfKing Sep. 16 at 3:58 PM

$EDSA trade update.

0 · Reply

AllPenniesNoDividends Sep. 15 at 4:21 PM

$EDSA How sad is it I don’t even check this stock for news anymore. Just dead money sitting around basically :/ Still holding out hope for a big pop sooner or later, but if I was holding my breath I would’ve passed out months ago lol

0 · Reply

pausiloy Sep. 15 at 11:10 AM

$EDSA ok now 10 sites...withdrawn 1 site Long Beach, California, United States, 90806-1701 Long Beach Memorial Medical Center Orange, California, United States, 92868-3201 University of California Irvine Medical Center Bradenton, Florida, United States, 34209-4617 Nova Clinical Research Boise, Idaho, United States, 83712-6241 St. Luke's Boise Medical Center Peoria, Illinois, United States, 61637-0001 OSF Saint Francis Medical Center Burlington, Massachusetts, United States, 01805-0001 Lahey Hospital and Medical Center Reno, Nevada, United States, 89502-1576 (Withdrawn) Renown Institute for Heart & Vascular Health New Brunswick, New Jersey, United States, 08901-1928 Robert Wood Johnson Medical School The Bronx, New York, United States, 10467 Montefiore Hospital - Moses Campus Toledo, Ohio, United States, 43608-2603 Mercy Health - St. Vincent Medical Center Oklahoma City, Oklahoma, United States, 73104-3609 The University of Oklahoma Health Sciences Center

0 · Reply

TheGhostOfEd Sep. 13 at 1:12 AM

$EDSA Wack, Par got his monthly shares. Guess that means he's still running the company. Oh well. There was a sliver of hope there for a second. Now we're back to reality being scammed by these r tard canadian shitbags.

0 · Reply

Moneyybaggs Sep. 12 at 7:05 PM

$EDSA 1K shares traded today with 1 hour to go in the trading session! RUFKM?!?! WACFJ!!! FYP!!! FMTT!!!

1 · Reply

TheGhostOfEd Sep. 11 at 7:06 PM

$EDSA It's a true miracle, hand to god, that the share price is evening trading in the $2+ range. This should easily be in penny land. Makes you wonder.

0 · Reply

TheGhostOfEd Sep. 11 at 7:04 PM

$EDSA Let's put things into perspective. In Feb 2025 they raised $15 million in gross proceeds to fund operations for another 6-8 quarters, with an emphasis on advancing their Vitiligo program. Now, 7 months later manufacturing of EB06 has still yet to be completed. Any reputable or forward thinking company would have mfg plans lined up well in advance of raising capital and would have had a plan to quickly execute post infusion. The company now forecasts this to be complete sometime in 2H2025 (calendar), which in Edesa parlance is February 2026. So another year ticks by, another $6-$8 million in burn, and zero progress on their pipeline. No headcount reductions, no restructuring, no advancement on their other assets. In fact, they've stopped work on EB07 as if doing nothing was already too much. How is this not clear evidence of defrauding investors? How can anyone say the company is operating in the best interest of stakeholder? Rhetorical q of course, it's impossible.

0 · Reply

Moneyybaggs Sep. 11 at 3:58 PM

$EDSA Eddy! You’ve gone FULL METAL JACKET on us. HBC was spot on two years ago!!! This company is a complete scam. FYP!!! You are a CFJ!!! FMTT!!!

0 · Reply

TheGhostOfEd Sep. 11 at 2:09 AM

$EDSA I hope Gary gets ARDS and then when he emails himself for expanded access, he deletes it. That definitely tracks.

0 · Reply

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 4 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Apr 28, 2025, 4:30 PM EDT - 5 months ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 4, 2025, 4:15 PM EDT - 5 months ago

Edesa Biotech Announces Chief Financial Officer Transition

Feb 14, 2025, 4:15 PM EST - 7 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 13, 2025, 7:00 AM EST - 7 months ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Dec 13, 2024, 4:30 PM EST - 9 months ago

Edesa Biotech Reports Fiscal Year 2024 Results

Oct 31, 2024, 8:15 AM EDT - 11 months ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Oct 21, 2024, 8:15 AM EDT - 11 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Sep 13, 2024, 7:38 PM EDT - 1 year ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Jun 24, 2024, 8:20 AM EDT - 1 year ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Apr 2, 2024, 9:00 AM EDT - 1 year ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 7, 2024, 8:45 AM EST - 1 year ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 4, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Feb 9, 2024, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Jan 4, 2024, 4:15 PM EST - 1 year ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Dec 15, 2023, 4:10 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2023 Results

Nov 20, 2023, 4:05 PM EST - 1 year ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Edesa Biotech to Participate in Swiss Biotech Day

Apr 4, 2023, 8:45 AM EDT - 2 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Mar 23, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 15, 2023, 8:10 AM EDT - 2 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Feb 10, 2023, 9:00 AM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 1, 2023, 8:15 AM EST - 2 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Jan 17, 2023, 8:30 AM EST - 2 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Dec 20, 2022, 8:30 AM EST - 2 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 16, 2022, 9:00 AM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2022 Results

Dec 2, 2022, 8:00 AM EST - 3 years ago

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Sep 30, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Sep 8, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Sep 7, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Aug 12, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Aug 3, 2022, 8:15 AM EDT - 3 years ago

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

KennyP007 Sep. 16 at 7:58 PM

$EDSA Fellow TWATS, , next weeks the 4 year anniversary of the BIG POP. Anyone expect any action ???

0 · Reply

BillionerOfKing Sep. 16 at 3:58 PM

$EDSA trade update.

0 · Reply

AllPenniesNoDividends Sep. 15 at 4:21 PM

0 · Reply

pausiloy Sep. 15 at 11:10 AM

0 · Reply

TheGhostOfEd Sep. 13 at 1:12 AM

0 · Reply

Moneyybaggs Sep. 12 at 7:05 PM

$EDSA 1K shares traded today with 1 hour to go in the trading session! RUFKM?!?! WACFJ!!! FYP!!! FMTT!!!

1 · Reply

TheGhostOfEd Sep. 11 at 7:06 PM

$EDSA It's a true miracle, hand to god, that the share price is evening trading in the $2+ range. This should easily be in penny land. Makes you wonder.

0 · Reply

TheGhostOfEd Sep. 11 at 7:04 PM

0 · Reply

Moneyybaggs Sep. 11 at 3:58 PM

$EDSA Eddy! You’ve gone FULL METAL JACKET on us. HBC was spot on two years ago!!! This company is a complete scam. FYP!!! You are a CFJ!!! FMTT!!!

0 · Reply

TheGhostOfEd Sep. 11 at 2:09 AM

$EDSA I hope Gary gets ARDS and then when he emails himself for expanded access, he deletes it. That definitely tracks.

0 · Reply

TheGhostOfEd Sep. 11 at 2:05 AM

$EDSA shithole country, shithole company....and Gary the last meaningful press release besides the BARDA one was November 2023. Let that sink in. Two years. No news. Fuck these guys. Such fucking scumbags.

0 · Reply

TheGhostOfEd Sep. 11 at 12:56 AM

$EDSA Still no form 4 for Par....maybe tomorrow? Fingers crossed the board maybe finally did the right thing and disposed of that scamming fucktard

0 · Reply

TheGhostOfEd Sep. 11 at 12:53 AM

$EDSA Bull For India

0 · Reply

TheGhostOfEd Sep. 11 at 12:53 AM

$EDSA Ya, I remember the Irish LOL

0 · Reply

Treb3k Sep. 10 at 10:35 PM

$EDSA remember when that account on this board was saying that par wanted to sell the company for billionS

0 · Reply

Elliot_A Sep. 10 at 4:58 PM

$EDSA There are usually some shenanigans at the beginning of the new fiscal year (i.e., Oct). Strategic inv in 2024, One-for-Seven Reverse Share Split in 2023, $3MM AtM in 2022, etc. Let’s see what happens in year.

1 · Reply

TheGhostOfEd Sep. 10 at 12:42 PM

$EDSA no one in their right mind can claim prudent use of capital by this company.....you don't spend four quarters on standby and not cut staff It's disgusting. Disgraceful. Impossible to say they are not defrauding investors. So many lies, improper disclosures and just general bullshit. The absolute worst people. Canada is truly a shithole country with such a pathetic work culture. Incompetent beyond belief.

1 · Reply

TheGhostOfEd Sep. 10 at 12:39 PM

$EDSA Getting selected by BARDA was not an accomplishment. They were going to proceed with the trial regardless so essentially they had to pick the best three assets they could find. It doesn't mean EB05 is anything special. It could be a 2/10 and still get picked because it's better than a 1/10....

0 · Reply

TheGhostOfEd Sep. 10 at 12:35 PM

$EDSA Whether the company is defrauding investors or is just insanely incompetent, it really doesn't matter because the outcome is the same. That outcome being nothing but more dilution. Look at the last three years. That's all the evidence you need. The company has very literally done nothing. Over the past 12 months in particular there hasn't been a single notweworty event. It's beyond pathetic. The employees of this company are losers. Milking salaries doing zero work. Leadership is even worse because they should in theory know what's going on. The top people at this company are invisible. Not a single one has a profile picture on their LinkedIn profile. Wonder why? That sure builds trust. Why the anonymity if running a publicity traded company? The reason is obvious...they all know investors are being defrauded to some level. Or if they don't they have like a 60 level iq which would indicate, as I have been saying, they are mentally retarded. So take your pick lol.

0 · Reply

TheGhostOfEd Sep. 10 at 1:37 AM

$EDSA how is this not a scam?

0 · Reply

TheGhostOfEd Sep. 10 at 1:37 AM

$EDSA They need to raise more capital so they can continue to do nothing 🤡🤡🤡🤡🤡

0 · Reply

pausiloy Sep. 10 at 12:39 AM

$EDSA ATM issue 2 million new shares, more dillusion and main investor sold all their 10% shares, sp will more likely bleed to sub 2

0 · Reply

Market Cap	16.89M
Revenue (ttm)	0.00
Net Income (ttm)	-6.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,600
Avg Vol	24,930
Day's Range	N/A - N/A
Shares Out	7.04M
Stochastic %K	46%
Beta	0.10
Analysts	Strong Sell
Price Target	$11.00